Treatment of advanced ovarian cancer with sequential combination chemotherapy
Thomas W. Griffin(Janssen (Belgium)), Mary E. Costanza(University of Massachusetts Chan Medical School), Thomas F. Halpin(St Vincent Hospital), Rowland N. Meyer(St Vincent Hospital), RICHARD A. HUNTER(University of Massachusetts Chan Medical School), Marcia K. Liepman(Memorial Hospital), Gary M. Strauss, Won K. Tak(University of Massachusetts Chan Medical School), Harry L. Greene(Vanderbilt University Medical Center), Joel H. Schwartz(University of Massachusetts Chan Medical School), Andrew I. Cederbaum(University of Minnesota), Allen Ward(University of Massachusetts Chan Medical School)
Cited by 14
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
American Cancer Society Guidelines for Breast Cancer Screening: Update 2003
|CA A Cancer Journal for Clinicians|2003|781
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
|European Urology|2014|273
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
|Journal of Clinical Oncology|1998|188